Efficacy of Fine-Needle Aspiration Cytology in Diagnosing Secretory Carcinoma of Salivary Gland: A Systematic Review and Meta-Analysis

被引:1
作者
Kala, Pooja Sharma [1 ]
Gupta, Mamta [1 ]
Thapliyal, Naveen [1 ]
机构
[1] Govt Doon Med Coll, Dept Pathol, Dehra Dun, India
关键词
Cytology; Mammary analog secretory carcinoma; Molecular testing; Parotid gland; Salivary gland; Secretory carcinoma; HIGH-GRADE TRANSFORMATION; PAROTID-GLAND; FEATURES; ENTRECTINIB; SERIES; MASC; TOOL;
D O I
10.1159/000536249
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Introduction: The diagnosis of salivary gland secretory carcinoma (SC) in fine-needle aspiration specimens is challenging because its low-grade nature makes it difficult to differentiate it from various benign or malignant salivary gland neoplasms. Currently, the gold standard is demonstration of ETV6-NTRK3 fusion gene. However, the decision for ordering this costly molecular testing can be facilitated by the correct recognition of its cytomorphological features. The aim of the review was to determine the accuracy of fine-needle aspiration cytology (FNAC) in diagnosis of salivary gland SC. The secondary objective was to recognize varied cytomorphological patterns, characteristic features of SC and differentiate it from other neoplasms. Methods: PubMed/MEDLINE, Science Direct, Embase, Cochrane review, and PROSPERO databases were searched for studies having the following key search terms: ("secretory carcinoma of salivary gland" OR "mammary analogue secretory carcinoma of salivary gland") AND ("Cytology" OR "Cytological features" OR "aspirate" OR "cytodiagnosis") published in the time frame of 2010 to June 2023. Studies reporting cytological features of the salivary gland tumors which were confirmed/diagnosed as SC on molecular investigation, were included in the systematic review. Finally, seventeen studies reporting a total of 45 cases were included in the metanalysis. Results: The sensitivity of the FNAC in diagnosing SC in salivary gland is 27.7% (95% CI: 16.6-42.5%). The LR+ (positive likelihood ratio) was 0.654 (0.344-1.245), LR- (negative likelihood ratio) was 1.023 (0.538-1.946), and diagnostic odds ratio was 0.421 (0.129-1.374). The molecular testing and/or immunohistochemistry performed on cell block increased the diagnostic accuracy. Conclusion: Recognition of subtle cytomorphological patterns, i.e., papillary formation, clusters, and singly dispersed cells along with presence of fine intracytoplasmic vacuolations were the characteristic findings in majority of cases, confirmed with diagnostic molecular profiling. This may be helpful in identification of this rare entity with limited published literature and help in increasing diagnostic accuracy.
引用
收藏
页码:83 / 106
页数:24
相关论文
共 62 条
[11]   Mammary analog secretory carcinoma of the parotid gland: A case of a 12-year-old Taiwanese girl [J].
Chen, Yen-Chun ;
Hsu, Hsin-Te ;
Lin, Yun-Ho ;
Chen, Lung-Che ;
Lin, Ya-Fang .
INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY CASE REPORTS, 2018, 20 :14-17
[12]   Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands [J].
Chiosea, Simion I. ;
Griffith, Christopher ;
Assaad, Adel ;
Seethala, Raja R. .
HISTOPATHOLOGY, 2012, 61 (03) :387-394
[13]   Salivary Gland Secretory Carcinoma With High-Grade Transformation, CDKN2A/B Loss, Distant Metastasis, and Lack of Sustained Response to Crizotinib [J].
Cipriani, Nicole A. ;
Blair, Elizabeth A. ;
Finkle, Joshua ;
Kraninger, Jennifer L. ;
Straus, Christopher M. ;
Villaflor, Victoria M. ;
Ginat, Daniel Thomas .
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2017, 25 (07) :613-618
[14]  
Darras Natasha, 2019, J Am Soc Cytopathol, V8, P157, DOI 10.1016/j.jasc.2019.01.006
[15]   Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic study of 11 cases [J].
Din, Nasir Ud ;
Fatima, Saira ;
Kayani, Naila .
ANNALS OF DIAGNOSTIC PATHOLOGY, 2016, 22 :49-53
[16]   What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) [J].
Drilon, A. ;
Li, G. ;
Dogan, S. ;
Gounder, M. ;
Shen, R. ;
Arcila, M. ;
Wang, L. ;
Hyman, D. M. ;
Hechtman, J. ;
Wei, G. ;
Cam, N. R. ;
Christiansen, J. ;
Luo, D. ;
Maneval, E. C. ;
Bauer, T. ;
Patel, M. ;
Liu, S. V. ;
Ou, S. H. I. ;
Farago, A. ;
Shaw, A. ;
Shoemaker, R. F. ;
Lim, J. ;
Hornby, Z. ;
Multani, P. ;
Ladanyi, M. ;
Berger, M. ;
Katabi, N. ;
Ghossein, R. ;
Ho, A. L. .
ANNALS OF ONCOLOGY, 2016, 27 (05) :920-926
[17]   Cytopathological Findings of Secretory Carcinoma of the Salivary Gland and the Diagnostic Utility of Giemsa Staining [J].
Egusa, Yuria ;
Nishimura, Midori Filiz ;
Baba, Satoko ;
Takeuchi, Kengo ;
Makino, Takuma ;
Tachibana, Tomoyasu ;
Nishikori, Asami ;
Fujita, Azusa ;
Yanai, Hiroyuki ;
Sato, Yasuharu .
DIAGNOSTICS, 2021, 11 (12)
[18]   Use of fluorescent in-situ hybridisation in salivary gland cytology: A powerful diagnostic tool [J].
Evrard, S. M. ;
Meilleroux, J. ;
Daniel, G. ;
Basset, C. ;
Lacoste-Collin, L. ;
Vergez, S. ;
Uro-Coste, E. ;
Courtade-Saidi, M. .
CYTOPATHOLOGY, 2017, 28 (04) :312-320
[19]   SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets [J].
Freiberger, Sandra N. ;
Brada, Muriel ;
Fritz, Christine ;
Holler, Sylvia ;
Vogetseder, Alexander ;
Horcic, Milo ;
Bihl, Michel ;
Michal, Michal ;
Lanzer, Martin ;
Wartenberg, Martin ;
Borner, Urs ;
Bode, Peter K. ;
Broglie, Martina A. ;
Rordorf, Tamara ;
Morand, Gregoire B. ;
Rupp, Niels J. .
NEOPLASIA, 2021, 23 (05) :473-487
[20]   Additional diagnostic features of mammary analogue secretory carcinoma on cytology [J].
Gonzalez, M. F. ;
Akhtar, I. ;
Manucha, V. .
CYTOPATHOLOGY, 2018, 29 (01) :100-103